Cilofungin (LY-121019) is a fungicidal cell wall-active 1,3-0-glucan synthetase inhibitor with a short plasma half-life and saturable nonlinear plasma pharmacokinetics. To optimize the in vivo efficacy of this compound, we studied the effects of its linear and nonlinear pharmacokinetics during continuous versus intermittent intravenous infusion of cilofungin in the treatment of experimental disseminated candidiasis in persistently granulocytopenic rabbits. Six groups of rabbits were studied, untreated controls (n = 32) and five cilofungin dosage regimen groups consisting of the following: 25 mg/kg of body weight intravenously twice daily (VLoINT) (n = 9); 50 mg/kg twice daily (LoINT) (n = 9); 90 mg/kg twice daily (HiINT) (n = 11); 5 mg/kg/h for 18 h/day (LoCI) (n = 7); and 10 mg/kg/h for 18 h/day (HiCI) (n = 7). All regimens achieved plasma concentrations exceeding the MIC for Candida albicans (0.25 pg/ml). In vitro timed kill assays found that the fungicidal activity and rate of kill by cilofungin above the MIC for C. albicans was concentration dependent. At the lower dosage regimens (VLoINT, LoINT, and LoCI), cilofungin followed linear plasma pharmacokinetics, whereas at higher doses (HiCI and HiINT), nonlinear kinetics consistent with a saturated elimination pathway(s) were observed. Only HiCI and HiINT produced a 103-to 104-fold reduction in CFU per gram in candidiasis of the brain (P c 0.001). HiCI and HiINT also significantly reduced infection in the choroid (P c 0.05). All regimens, except VLoInt, significantly (P c 0.01) reduced tissue infections in lung, liver, spleen, and kidney. However, only the regimens with nonlinear saturation kinetics (HiCI and HiINT) produced a 106 reduction in the spleen and a > 105 reduction of C. albicans in the kidney and liver. A simple doubling of the dosage from LoCI to HiCI resulted in tissue concentrations that were 10 times higher and a 102-to 104-fold-greater antifungal effect. There was a direct correlation (r2 = 0.83) between tissue concentrations of cilofungin and antifungal activity. Thus, continuous and intermittent infusion dosage regimens that elicit nonlinear saturation plasma pharmacokinetics of cilofungin were associated with increased antifungal activity against experimental disseminated candidiasis.
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Cilofungin (LY-121019) is a semisynthetic lipopeptide of the echinocandin class of antifungal compounds (4, 11, 12) . Cilofungin and other echinocandins are fungicidal agents that block 1,3-,-glucan synthetase and disrupt fungal cell wall biosynthesis (12, 24, 27) . Cilofungin has in vitro activity against Candida species, particularly Candida albicans and C. tropicalis (11-13, 18, 19, 22, 25) , and was found to be fungicidal during in vitro timed kill assays (14) . Cilofungin also has been found to be active in vivo against invasive aspergillosis (5) .
The echinocandin class of 1,3-p-glucan synthetase inhibitors also has activity against Pneumocystis carinii. Cilofungin (10) and the echinocandin compound L-671,329 have been found in vivo to be effective against Pneumocystis pneumonia (24) . That P. carinii and fungi should share a similar molecular target in their cell wall would be predicted on the basis of the close phylogenetic relationship between P. carinii and some fungi (7) . Thus, understanding the pharmacodynamic dynamic properties of the 1,3-p-glucan synthetase inhibitors may potentially improve therapeutic * Corresponding author. approaches to life-threatening infections due to Candida spp., Aspergillus spp., and P. carinii.
Gordee et al. found that cilofungin administered at 50 mg/kg of body weight intraperitoneally was as active as similar doses of amphotericin B in reducing the recovery of C. albicans from the kidneys (11) . More recently, however, Padula and Chambers observed that cilofungin was not effective in a rabbit model of Candida endocarditis when a dosage of 50 mg/kg intravenously (i.v.) twice daily for 7 days was used (20 (21) .
This disparity between the potent in vitro fungicidal activity and the paucity of antifungal effect in vivo may be due to the relatively short plasma half-life of cilofungin and the lack of central nervous system (CNS) penetration of the large echinocandin molecule. For example, although the peak plasma concentration (Cmax) of cilofungin in rabbits after a 50-mg/kg i.v. dose was 297 + 39 jig/ml (nearly 500 times the MIC for 90% of the isolates of C. albicans), the compound was not detectable in plasma 2 h after injection (beta phase half-life = 12.9 + 0.7 min) and the area under the plasma concentration-time curve (AUC) for this dosage was small (15) . Further 4 ,000 x g for 10 min; the pellet was resuspended and washed three times with 0.9% NaCl. The inoculum was adjusted by hemacytometer and serial dilutions to a concentration of 104 organisms per ml (predominantly blastoconidia in singlets and doublets). Hemacytometer counts were verified by 10-fold serial dilution of the suspension onto Sabouraud glucose agar plates. The total inoculum of 2.5 x 104 to 5.0 x 104 CFU for each rabbit was suspended into 5 ml of sterile 0.9% NaCl, administered slowly via the indwelling silastic i.v. catheter. Antifungal therapy was initiated 24 h after inoculation.
Drug for parenteral administration. Cilofungin was provided by Eli Lilly & Co. as a lyophilized powder. A 50-mg/ml solution was prepared by dissolving the powder in 33% polyethylene glycol (PEG) 300 (Sigma Chemical Co., St. Louis, Mo.) and phosphate-buffered (pH 6.8) physiologic saline. Gentle agitation in an ultrasonic water bath facilitated dissolution. The solution was stored at 4°C and used within 48 h. This concentrated solution of cilofungin (50 mg/ml) was prepared to avoid large volumes of PEG, which were found in preliminary studies to be toxic to rabbits. Dosage regimens. Five dosage regimens were studied: high dose intermittent (HiINT); low dose intermittent (LoINT); very low dose intermittent (VLoINT); high dose continuous infusion (HiCI); and low dose continuous infusion (LoCI). Concurrent untreated control rabbits were studied during investigation of each dosage regimen. The VLoINT regimen yielded a total daily dosage of 50 mg/kg/day. The LoCI and LoINT regimens yielded similar total daily dosages of 90 and 100 mg/kg/day, respectively. The HiCI and HiINT regimens also yielded equivalent total daily dosages (180 mg/kg/day).
Intermittent infusion. Starting 24 h after inoculation, cilofungin was administered slowly as an intermittent i.v. Tissues were grouped by whether they were neural (cerebrum, cerebellum, vitreous, and chorioretina) or extraneural (lung, liver, spleen, kidney, and quadriceps) in origin.
Antifungal activity was also determined qualitatively by the presence or absence of lesions in tissues and by histopathological inspection of selected tissues. Representative tissue blocks were fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin, periodic acid-Schiff, and methenamine silver.
Plasma and tissue concentrations of cilofungin. Plasma and tissue levels of cilofungin were determined by a microbiological agar diffusion method, using Aspergillus montevidensis A35137 (11) . Standard plasma samples were made by adding cilofungin to 50% methanol-50% sodium phosphate buffer (pH 6) at 1,000 ,ug/ml and then diluting with 25% methanol-25% sodium phosphate buffer (pH 6)-50% control rabbit plasma to obtain final cilofungin concentrations of 0.3, 0.5, 1.0, and 2.0 ,ug/ml. Plasma samples were diluted with 50% methanol-50% buffer (pH 6) so that resulting zone sizes were within the range of the standard curve concentrations. All dilutions were adjusted such that each sample contained the same amount of plasma present in the standard curve samples.
A. montevidensis was grown on V-8 Juice agar medium for 3 days at 30°C. The Aspergillus conidia were harvested by streaking a sterile swab repeatedly over the agar plate flooded with 5 to 10 ml of saline. This conidial saline suspension was then adjusted to an optical density of 0.6 at 590 nm on a Bausch & Lomb Spectronic 20 spectrophotometer. Each 100 ml of melted and cooled (50°C) Bacto Antibiotic Assay Medium agar (Difco Laboratories, Detroit, Mich.) was inoculated on the day of assay with 3 ml of this spore suspension. A 300-ml amount of this seeded agar was poured onto a glass plate (12 A standard plasma concentration curve was made by plotting the logarithm of the known cilofungin concentration against the unweighted average of the three zone diameters for each standard sample. The average of the three zone diameters for each sample was then used to read the sample's concentration off the curve. There was a good linear relationship between the log of the concentrations and the zone diameters, with a correlation coefficient of 0.9937. The sensitivity of the method was 0.6 ,ug/ml, and the coefficient of variation at 4 [Lg/ml for both interday and intraday variation was 4%.
Sections of liver, spleen, lung, kidney, cerebrum, cerebellum, and choroid obtained at postmortem examinations were studied for tissue concentrations of cilofungin in a manner similar to that described above. Each sample was weighed, diluted with 10 ml of 50% methanol-50% buffer (pH 6) per g of tissue, and then homogenized in a Polytron homogenizer (Brinkmann Instruments, Westbury, N.Y.). The sample was then centrifuged for 10 min at 2,000 rpm, and the supernatant was assayed as described above. The standard curves for each tissue, using tissue homogenates from untreated control rabbits, were prepared in 50% methanol-50% sodium phosphate buffer (pH 6). Further dilution with buffer was performed as necessary. Samples of vitreous humor were diluted as required to obtain zones within the standard curve range with 50% methanol-50% buffer (pH 6). The sensitivity, linearity, and reproducibility of the assay in tissues were similar to those obtained in plasma.
Pharmacokinetic calculations. For the single doses of intermittently dosed cilofungin, the AUC was calculated by using the linear trapezoidal rule up to the final measured concentration and then extrapolating to infinity (9) . The terminal half-life (t1/2) in the postdistributive phase was determined by regression analysis, using an unweighted least linear squares method. The volume of distribution at steady state (V) was determined by using the area under the moment curve. The clearance (CL) was calculated by dividing the dose by the AUC.
To determine the relation between clearance of Candida spp. from tissue and cilofungin tissue levels, the geometric mean concentrations of Candida spp. (CFU per gram) in each tissue were compared with the mean tissue concentrations of cilofungin. Tissue concentrations and antifungal activity were studied in three CNS tissues (cerebrum, cerebellum, and choroid) and in four non-CNS tissues (liver, spleen, kidney, and lung) from HiCI and LoCI rabbits. These comparisons were analyzed by using Spearman rank correlation coefficients. RESULTS Pharmacokinetics. Dosing regimens VLoINT, LoINT, and LoCI gave plasma concentration-time curves that followed linear plasma pharmacokinetics, whereas regimens HiCI and HiINT resulted in nonlinear plasma pharmacokinetics consistent with a saturable elimination pathway(s). Following simple first-order kinetics, the HiCI dosage would have attained a steady-state plasma concentration of 5 p.g/ml. Instead, HiCI demonstrated nonlinear saturation kinetics, as depicted in Fig. 1 .
The intermittent infusion dosages (VLoINT and LoINT) also followed simple first-order plasma pharmacokinetics. However, the highest intermittent dosage (HiINT) followed saturation plasma pharmacokinetics (Fig. 2) . Following firstorder kinetics, the plasma level of cilofungin at 90 mg/kg would have been predicted to decline to <1 pg/ml by the end of 2 h; however, a mean plasma level of <1 1g/ml was not attained until >18 h after the first dose. Following subsequent doses, the HiINT regimen further showed nonlinear saturation kinetics, with accumulation to >10 pLg/ml by the end of the 10th dose.
The effect of a simple doubling of the cilofungin dosage from LoCI to HiCI or from LoINT to HiINT resulted in a manifold-higher AUC, as the plasma pharmacokinetics changed from linear to nonlinear. For example, the steadystate AUC (per 18-h infusion period) of HiCI increased in comparison to LoCI by >50-fold, from 90 to 5,220 pLg/ml/h, consistent with saturation nonlinear kinetics. Similarly, when the LoINT (50 mg/kg, twice daily) dosage was increased nearly 2-fold to the HiINT (90 mg/kg, twice daily) dosage, the AUC increased by 7-fold at the first dose from 30 to 216 ,ug/ml/h and by 67-fold to 2,008 p.g/ml/h after the tenth dose.
Timed kill assays. The fungicidal activity and rate of kill by cilofungin were concentration dependent (Fig. 3) . After 24 h, a -10-fold kill was achieved at 0.5 pg/ml, a 2103-fold kill was achieved at 1.0 ,ug/ml, and a-105-fold kill was achieved at 5.0 pg/ml.
In vivo antifungal activity. Six groups of rabbits were studied, i.e., untreated controls (n = 32) and the following five cilofungin dosage regimen groups: 25 mg/kg i.v. twice daily (VLoINT) (n = 9); 50 mg/kg twice daily (LoINT) (n = 9); 90 mg/kg twice daily (HiINT) (n = 11); 5 mg/kg/h for 18 h/day (LoCI) (n = 7); 10 mg/kg/h for 18 h/day (HiCI) (n = 7). The antifungal activity of the different dosing regimens of cilofungin in CNS tissue is depicted in Fig. 4 . The dosing regimen VLoINT, following linear pharmacokinetics, had no effect on clearing CNS tissue in comparison to untreated controls. Dosing regimens LoINT and LoCI, also following linear pharmacokinetics, similarly had no effect on candidiasis of the brain. Only dosing regimens HiCI and HiINT, following nonlinear saturation kinetics, produced a 103-to 104-fold reduction in CFU per gram in candidiasis of the cerebrum, cerebellum, and choroid (P c 0.001). All dosage regimens reduced infection in the vitreous humor with borderline significance (P < 0.05).
The antifungal activity of the different dosing regimens of cilofungin in extraneural visceral tissues is depicted in Fig. 5 . All regimens, except VLoINT, significantly (P c 0.01) reduced tissue infections in lung, liver, spleen, and kidney, producing a .102 decrease in CFU/g. However, only the nonlinear regimens (HiCI and HiINT) produced a 106 reduction in the spleen (P c 0.0001) and a >10' reduction of Candida CFU per gram in the kidney and liver (P c 0.0005) in comparison to untreated controls.
Tissue concentration of cilofungin and clearance of Candida spp. There was a direct correlation between tissue concentrations of cilofungin and antifungal activity. rabbits each receiving high-or low-dose, continuous-infusion cilofungin, thus representing a total of 98 tissue samples. Doubling of the dosage from LoCI (5 mg/kg/day) to HiCI (10 mg/kg/day) resulted in tissue concentrations that were 10 times higher and a 102-to 104-fold greater antifungal effect.
DISCUSSION
This study demonstrated that administration of cilofungin by high-dose continuous infusion or by high-dose intermittent infusion resulted in nonlinear saturation plasma pharmacokinetics and that these nonlinear pharmacokinetic properties were associated with a significantly improved antifungal activity in treatment of invasive candidiasis in neural and extraneural tissues. Only the HiCI and HiINT regimens, which followed nonlinear saturation kinetics, achieved both high plasma cilofungin levels and sustained levels throughout the entire dosing cycle. Tissue concentrations of ciofungin correlated directly with in vivo antifungal activity and were consistent with the results from in vitro timed kill assays, which also demonstrated concentrationdependent fungicidal activity. effect in comparison to untreated controls or less effect in comparison to that of amphotericin B (20, 21) . Although cilofungin is a potent fungicidal agent in vitro, its short plasma half-life when following linear plasma kinetics may have prevented it from exerting a sustained antifungal effect in vivo.
By comparison, sustained plasma levels from the intraperitoneal sites of injection of cilofungin may also have accounted for cilofungin's potent activity, comparable to that of amphotericin B found in a murine model of disseminated candidiasis by Gordee et al. (11) . Two other studies have also suggested improved antifungal activity of cilofungin as a result of continuous infusion (3, 23 indicate that sustained levels of cilofungin may augment its in vivo activity.
The key to augmentation of cilofungin's in vivo activity may be the nonlinearity of its Michaelis-Menten-like saturation plasma pharmacokinetics. Antifungal activity of cilofungin was augmented when plasma levels several times above the MIC were sustained over time, achieving effects that are similar to the concentration-dependent fungicidal activity observed in the in vitro timed kill assay. One should note, however, that continuous infusion is not the only means by which to establish these higher plasma levels. For example, once clearance of cilofungin was saturated by a high intermittent dosage, as observed in the HiINT regimen, the clearance decreased and the AUC of cilofungin markedly increased. Thus, a dosage regimen of cilofungin that elicits nonlinear plasma pharmacokinetics and higher sustained plasma levels may augment its in vivo antifungal activity.
The striking augmentation of in vivo antifungal activity achieved by the nonlinear HiINT and HiCI regimens, especially in the CNS tissues, are apparently not explainable by a simple doubling of the total daily dosage. A simple doubling of the dosage from LoCI to HiCI resulted in tissue concentrations that were 10 times higher and a 102_ to 104-fold greater antifungal effect. The LoINT regimen achieved peak levels nearly 100-fold higher than the MIC, but these levels were sustained for only a brief time. The LoCI regimen had sustained but relatively low plasma levels approximately five times the MIC; these sustained but relatively low plasma levels may have been insufficient to achieve adequate fungicidal tissue concentrations. Only the HiCI and HiINT regimens achieved both high plasma cilofungin levels and sustained levels throughout the entire dosing cycle. Of note, our recent studies of amphotericin B in the treatment of disseminated candidiasis in our rabbit model of hepatosplenic candidiasis have found that a simple doubling of the dosage between 0.6 and 1.2 mg/kg/day did not cause differences of antifungal activity comparable to those observed in the dosing regimens of cilofungin obtained from doubling its dosage at the linear and nonlinear interfaces, especially in the CNS.
The relative contributions of peak serum concentrations and AUC of cilofungin cannot be completely determined from this study. Indeed, the most critical factor for the superiority of a given dosing regimen may be the presence of nonlinear saturation-type pharmacokinetics. Given the findings of this study, subsequent experiments could be designed to compare increasing AUCs achieved by both continuous and intermittent infusion at different dosing intervals (e.g., 4, 6, 8, 12 , and 24 h) while maintaining the same total daily dosage. Such experiments would be technically demanding but would possibly provide considerable insight into the pharmacodynamics of echinocandins.
The HiINT regimen was associated with acute histamine release (a phenomenon observed in humans receiving rapid infusions), whereas the HiCI regimen gradually achieved plasma concentrations of >100 ,ug/ml without the effect of acute histamine release. Perhaps higher doses of echinocandins in humans could be better tolerated by continuous infusion or slowly administered intermittent infusions.
Another issue of toxicity with cilofungin and other echinocandins is that of the carrier. During preliminary studies of cilofungin in our laboratory, larger volumes of PEG (.10 ml/kg) were used in accordance with the methods used in the earlier murine studies. These larger volumes of PEG were poorly tolerated and resulted in somnolence, weakness, and azotemia. The PEG was well tolerated, however, when cilofungin was concentrated into 50 mg/ml. Whether PEG is an appropriate solubilizing agent for cilofungin in human trials may depend on the volume of PEG administered. Small volumes of PEG may be well tolerated. Alternatively, other solubilizing agents, including 3-cyclodextran and liposomes, should be considered for this class of compounds.
The antifungal effect of nonlinear dosage regimens versus other regimens in this study was most striking in the CNS. Perhaps the sustained plasma concentrations permit slow penetration of the large echinocandin molecule across the blood-brain barrier to achieve therapeutic tissue concentrations. Whether the antifungal activity of cilofungin resides in tissue or plasma cannot be fully answered from this study. However, if plasma concentrations were the only factor responsible for in vivo antifungal activity, one would not expect to see the striking differences of antifungal activity in CNS and non-CNS tissues. The LoCI regimen had a minimal effect in cerebrum and cerebellum, in which tissue concentrations of cilofungin were low, whereas the same regimen had a significant effect in reducing Candida concentrations in the non-CNS tissues of liver, spleen, and kidney, in which tissue concentrations were 10 to 20 times higher.
The effects of nonlinear pharmacokinetics of cilofungin in this study may be applicable to other members of the echinocandin class of glucan synthetase inhibitors, as well as to other classes of fungal cell wall-active compounds. Cilofungin represents one member of the echinocandins. Other promising echinocandin compounds have been described before (2, 8) . Some members of the echinocandin class of cell wall-active agents, other than cilofungin, appear to have similar properties of relatively short plasma half-lives at alpha and beta phases as in L-671,329 (26 could potentially achieve the high peak plasma concentrations and sustained plasma levels that appear to be required for optimal fungicidal activity of these compounds. Whether other 1,3-p-glucan synthetase inhibitors follow nonlinear saturable plasma kinetics associated with increased pharmacodynamic activity remains to be determined.
